Barclays PLC Boosts Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Barclays PLC grew its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 81.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 83,582 shares of the medical instruments supplier’s stock after acquiring an additional 37,394 shares during the period. Barclays PLC owned about 0.21% of AngioDynamics worth $651,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Quarry LP lifted its position in AngioDynamics by 75.1% during the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 2,594 shares during the period. CWM LLC lifted its holdings in shares of AngioDynamics by 981.3% in the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock valued at $76,000 after buying an additional 8,832 shares during the period. Mackenzie Financial Corp acquired a new position in shares of AngioDynamics in the 2nd quarter valued at about $80,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of AngioDynamics in the third quarter worth about $86,000. Finally, AE Wealth Management LLC acquired a new stake in AngioDynamics during the second quarter worth about $87,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Stock Up 4.9 %

Shares of AngioDynamics stock opened at $12.77 on Friday. The firm has a market cap of $516.80 million, a PE ratio of -2.27 and a beta of 0.59. The business has a 50-day moving average price of $8.65 and a 200 day moving average price of $7.60. AngioDynamics, Inc. has a twelve month low of $5.26 and a twelve month high of $13.13.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The business had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. During the same period in the previous year, the business earned ($0.05) earnings per share. The business’s revenue was down .1% compared to the same quarter last year. On average, sell-side analysts expect that AngioDynamics, Inc. will post -0.36 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on ANGO shares. HC Wainwright boosted their price target on AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a report on Friday, January 10th. Canaccord Genuity Group decreased their target price on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, October 4th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.